V-Mart Retail shares slip 6% despite strong Q4 results, bonus issue announcement
Shares of V-Mart Retail fell as much as 6.2 per cent on Monday to Rs 3,161.15 on the BSE, even as the company reported a turnaround in its financial performance for the March 2025 quarter and announced a 3:1 bonus share issue.
For the quarter ended March 2025, the value fashion retailer posted a net profit of Rs 19 crore, a sharp reversal from a loss of Rs 39 crore in the same quarter a year earlier. Revenue for Q4FY25 rose 17 per cent year-on-year to Rs 780 crore, up from Rs 669 crore in the March 2024 quarter.
Operational performance also improved, with earnings before interest, tax, depreciation and amortisation (EBITDA) rising to Rs 68 crore in the fourth quarter of FY25 from Rs 40 crore a year ago.
Meanwhile, the company's board of directors approved a bonus share issue in the ratio of 3:1. For every one existing fully paid-up equity share of Rs 10 each, shareholders will receive three additional shares of the same face value. The bonus issue is subject to shareholder approval.
The record date for determining bonus share eligibility will be announced later. Investors must own shares at least one trading day prior to the record date to qualify for the bonus.
The board did not recommend a dividend for the financial year 2024–25, opting to retain earnings to support the company's future growth initiatives.
Despite a 45 per cent gain over the past year, V-Mart Retail shares have fallen more than 9 per cent in the last three months. The stock is currently trading below six of its eight key daily moving averages—the 5, 10, 20, 100, 150, and 200-DMA—suggesting prevailing bearish momentum.
The stock's Relative Strength Index (RSI) stands at 64.6, indicating it is neither oversold nor overbought.
READ SOURCE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
What Is Term Insurance and Why Is It a Smart Investment?
Life is uncertain, and it pays to save for the unexpected. Saving your loved ones' financial well-being may be as good an idea as you can get, and term life insurance may just be the answer. But what is term insurance, and why would you make it a smart investment? Let's see. Understanding Term Insurance Term insurance is a form of life insurance that insures for a fixed term or 'term.' If death occurs to the insured person during the term, the policy pays a pre-specified amount, the death benefit, to the nominee. Term insurance is unlike other life insurance policies because it does not include a maturity benefit i.e., nothing is paid back if the policyholder outlives the term. The only virtue is the simplicity of term insurance. There is nothing other than giving your loved ones financial protection without loading investment features, making it one of the cheapest and budget-friendly products in the market. Term life cover is a useful, timely fiscal buffer to families with young dependents during adverse times. Why Term Insurance Is a Good Investment? Cheap Premiums for Full Coverage: Term insurance is made into a maximum life cover in the smallest sums. For example, a young and healthy person can obtain a high coverage value Rs. 1 crore, say for a few thousand rupees per year. The affordability thus provided means that even people of modest means can provide for their family's future. Tailored to Your Requirements: Each person is born with different needs. Term insurance helps you decide the coverage, policy duration, as well as riders such as critical illness cover or accidental death benefit. This way, your policy becomes very easily available to your needs and finances. Tax Benefits: Term insurance is also tax advantageous under Section 80C of the Income Tax Act. Your earnings, to which the premium payments made by you are adjusted, lower your tax outflow. Also, the death benefit to your nominee is exempt from tax under Section 10(10D). Therefore, term insurance is an economically sound choice. Peace of Mind: The primary purpose of term insurance is to provide peace of mind. Knowing that your family will have financial support even in your absence is invaluable. Whether it's covering household expenses, paying off loans, or funding your child's education, term insurance ensures that your loved ones are not burdened financially. Encourages Financial Discipline: By investing in term insurance, you are giving more importance to the health of your family rather than going on unnecessary expenses. It makes you create some sort of financial discipline in which you think ahead. Selecting the Best Life Insurance Plan While selecting the best policy of life insurance, there are some things to be kept in mind. The following are a few tips that would help you make the correct choice: Assess Your Needs: Take into consideration your family's financial requirements, such as daily expenditures, current debts, and future objectives like higher education of your child or retirement of your spouse. Based on this, you'll be in a position to ascertain the amount of cover and the term of the policy. Compare Policies: Do not settle for the first product you find. Compare a number of products from different insurers to find the one that gives the best benefits at the lowest premium. Reputation of the Insurer: The ratio of claims settlement is something to be given weightage. It indicates the reliability of the insurer in settling claims. The larger the ratio, the more reliable he is. Read the Fine Print: Read the terms and conditions carefully when you're about to close the policy. Know exclusions, waiting periods, and other essential points. Use Online Tools: The larger insurance companies offer online calculators that assist in estimating the premium for the coverage you want. This helps to select the best life insurance plan that suits your needs. Term Insurance and Old Life Insurance Plans While both traditional life insurance plans and term insurance provide protection, there exists a major difference between them: Cost: Term insurance is cheaper than traditional plans since it does not provide life coverage alone. Traditional plans are equipped with savings or investment, which adds to premiums. Term insurance is cheaper than traditional plans since it does not provide life coverage alone. Traditional plans are equipped with savings or investment, which adds to premiums. Benefits: Term insurance offers a large sum assured at a low premium, whereas traditional plans provide a low life coverage with a maturity benefit. Term insurance offers a large sum assured at a low premium, whereas traditional plans provide a low life coverage with a maturity benefit. Purpose: Term insurance is ideal if your main purpose is to pay for your family's future. If protection comes together with savings, then old plans would be preferable. With this knowledge, you can select the plan that suits your money objectives best. The Role of Term Insurance in Financial Planning A good financial plan must include long- and short-term objectives. Term insurance can help in the following ways: Debt Management: It prevents your loved ones from inheriting debts such as home loans or personal loans. It prevents your loved ones from inheriting debts such as home loans or personal loans. Education and Career: The death benefit can be used for funding the education and career of your children, providing them with a secured future. The death benefit can be used for funding the education and career of your children, providing them with a secured future. Wealth Preservation: It prevents the need to draw on savings or sell investments to fund current expenses at the time of your death. As part of your overall financial plan, including term insurance protects your loved ones and also offers a great addition to your other investments, as it becomes a solid foundation. Myths regarding Term Insurance Although it is beneficial in numerous ways, term insurance is largely misunderstood. Let us eliminate some of the common myths: Myth 1: 'It's costly.' Truthfully, term insurance is among the cheapest kinds of life insurance. Myth 2: 'I don't need it if I'm young and healthy.' Buying term insurance at a young age ensures lower premiums and better coverage. Myth 3: 'No maturity benefit means no returns.' While term insurance doesn't provide returns, it offers unparalleled financial security for your family. Myth 4: 'The process of claim is complex.' It has been made simple for the majority of insurers so that it is easy for the nominees. Conclusion: A Lifelong Investment in Security Term insurance is not merely a policy; it's a guarantee to secure your family's future. Affordability, flexibility, and a concentration on protection make term insurance an intelligent choice for people of all ages. As a young professional or a parent who wishes to secure your child's future, term insurance guarantees that your loved ones are taken care of even without you. So don't procrastinate until tomorrow to secure today's most valuable items. Comparison shop for your selection, shop around, and select the optimal life insurance policy that's suitable for you. Keep in mind, investing money in term insurance isn't just a money choice it's a choice to peace of mind and a brighter future for your loved ones. Ahmedabad Plane Crash
Business Upturn
7 hours ago
- Business Upturn
Jubilant Group initiates block deals; Bhartia family to offload stake across key listed entities
In a significant market development, the Bhartia family, promoters of the Jubilant Group, is set to offload stakes in three of its listed companies via block deals, according to sources cited by Yatin Mota and CNBC Awaaz. Jubilant FoodWorks A major portion of the transaction involves Jubilant FoodWorks, where the promoters will sell 2% stake, amounting to 1.32 crore shares. The floor price has been fixed at Rs 641 per share, and Morgan Stanley is reportedly managing the deal. Other Group Companies Jubilant Pharmova : Around 56 lakh shares are expected to be offloaded. Jubilant Ingrevia: Approximately 1.2 crore shares will be sold. These strategic block deals come at a time when the group may be looking to rebalance holdings or raise funds for business needs. Market participants are closely watching the implications of this multi-company stake sale, especially given the group's significant presence in the food, pharma, and chemical sectors. More details are awaited as the deals are executed on the bourses. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
8 hours ago
- Yahoo
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16th – 19th in Boston, Massachusetts. Rakovina Therapeutics' management will participate in one-on-one partnering meetings throughout the conference with leading global pharmaceutical and biotechnology companies. The Company will showcase its pipeline of novel DNA damage response (DDR) inhibitors, including drug candidates discovered through its proprietary AI-driven platforms—Deep Docking and Variational AI's generative technology. These collaborations have produced promising compounds with potential applications in DDR-targeted oncology therapies, including candidates capable of penetrating the blood-brain barrier and addressing significant unmet medical needs in the treatment of cancer. KT-3000 Series The KT-3000 series is a novel class of dual-function small molecule inhibitors combining PARP and histone deacetylase (HDAC) inhibition in a single agent. Published pre-clinical data demonstrate that lead candidates for the kt-3000 series retain anti-tumor activity in cancers that are resistant to treatment with FDA-approved PARP inhibitors. The KT-3000 program presents an attractive partnering opportunity for companies seeking to expand their oncology portfolios with multi-functional agents that can be developed across a range of solid tumor indications. Rakovina is actively exploring collaborations to accelerate development and broaden the clinical utility of this program. KT-2000AI Series The KT-2000 series features highly selective PARP1 inhibitors designed to penetrate the blood-brain-barrier, addressing a critical unmet need in the treatment of primary and metastatic brain tumors. The Company previously announced that it had used its proprietary AI algorithm to screen billions of potential drug candidates to identify potential best-in-class lead candidates. By targeting PARP1 specifically—while sparing PARP2—the KT-2000 compounds are anticipated to deliver potent anti-tumor activity with an improved safety profile. The program is well positioned for strategic partnerships focused on advancing therapies for glioblastoma and other CNS-involved cancers, where few targeted options exist. KT-5000AI Series The KT-5000 series focuses on highly selective ATR inhibitors, a key target in the DNA damage response pathway. ATR inhibition has emerged as a promising strategy to exploit tumor vulnerabilities in cancers. Rakovina's AD-derived KT-5000 candidates are engineered for optimal selectivity and tolerability, positioning them for combination use with other DDR-targeted agents or standard-of-care therapies. The program represents a significant opportunity to address a wide range of solid tumors with high unmet medical need. 'The Rakovina Therapeutics team has advanced multiple programs from discovery to pre-clinical validation in our laboratories at the University of British Columbia. We look forward to engaging with potential partners who share our vision of accelerating breakthrough therapies through the integration of artificial intelligence and oncology expertise,' said Jeffrey Bacha, Executive Chairman. 'BIO provides an opportunity to both continue and initiate strategic discussions to drive long-term value through collaboration.' Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and AI-powered discovery capabilities. The Company anticipates that upcoming milestones—including lead optimization data and new target nominations—will further enhance its strategic positioning. For more information or to schedule a meeting with Rakovina Therapeutics management at BIO, please contact: Michelle Seltenrich, Director, Corporate Development – About BIO International Convention The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready. For more information: About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@ in to access your portfolio
